4//SEC Filing
INTERCEPT PHARMACEUTICALS INC 4
Accession 0001144204-15-058164
CIK 0001270073operating
Filed
Oct 4, 8:00 PM ET
Accepted
Oct 5, 9:01 PM ET
Size
12.3 KB
Accession
0001144204-15-058164
Insider Transaction Report
Form 4
Adorini Luciano
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2015-10-01+649→ 12,608 total - Award
Common Stock
2015-10-01+1,250→ 11,959 total - Award
Option to Purchase Common Stock
2015-10-01+3,250→ 3,250 totalExercise: $161.16Exp: 2025-10-01→ Common Stock (3,250 underlying) - Exercise/Conversion
Restricted Stock Units
2015-10-01−649→ 649 total→ Common Stock (649 underlying)
Footnotes (4)
- [F1]25% of the shares of restricted stock will vest on January 1, 2016, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remaining shares of restricted stock will vest pro rata on every subsequent three-month anniversary of the initial vesting date through January 1, 2019 (representing the vesting on each such vesting date of 6.25% of the shares of restricted stock), subject to the terms and conditions of the award and the 2012 Plan.
- [F2]25% of the shares of common stock underlying this option will vest on January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2019 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan.
- [F3]Conversion of restricted stock units ("RSUs") to shares of common stock on a one-to-one basis.
- [F4]On November 16, 2012, the reporting person was granted 10,384 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 6.25% of the shares underlying the RSUs, became vested on October 1, 2015, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest on January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan.
Documents
Issuer
INTERCEPT PHARMACEUTICALS INC
CIK 0001270073
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001270073
Filing Metadata
- Form type
- 4
- Filed
- Oct 4, 8:00 PM ET
- Accepted
- Oct 5, 9:01 PM ET
- Size
- 12.3 KB